FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2083963669> ?p ?o ?g. }

• W2083963669 endingPage "299" @default.
• W2083963669 startingPage "291" @default.
• W2083963669 abstract "Pancreatic adenocarcinoma is characterized by poor prognosis, late diagnosis and lack of response to conventional therapies. The incidence of this disease shows no sign of declining in the Western world. Thus, new targets need to be identified for pancreatic cancer treatment. In particular, new chemotherapeutic agents would be extremely beneficial for control of unresectable cancer and metastatic lesions as well as for prevention of this deadly disease. Mounting evidence suggests that both lipoxygenases (LOXs) and cyclooxygenases (COXs), the key enzymes for arachidonic acid metabolism, have a profound influence on the development and progression of several human cancers. Recent evidence suggests that both COX and LOX pathways are important in pancreatic cancer. Results from immunocytochemical, RT-PCR, and Western blotting studies have shown that COX, specifically COX-2, is upregulated in human pancreatic cancer cell lines as well as human pancreatic cancer tissues compared with normal ductal cells and normal pancreas specimens. Agents that block COX enzymes significantly inhibit pancreatic cancer growth both in vitro and in vivo, in parallel with induction of apoptosis. Expression of both 5-LOX and 12-LOX is also seen in pancreatic cancer, although compared to the expression of COX this has not been extensively investigated. Chemical inhibitors or antisense oligonucleotides that block either 5-LOX or 12-LOX cause marked inhibition of pancreatic cancer cell proliferation. On the other hand, LOX metabolites stimulate growth of the tumor cells and reverse LOX-inhibitor-induced growth inhibition, suggesting the specific role of LOX in regulating pancreatic cancer cell proliferation. Although questions still need to be answered, such as the underlying mechanisms for COX and LOX-induced growth inhibition, both COX and LOX pathways are potential targets for pancreatic cancer treatment and chemoprevention. COX and LOX enzyme inhibitors are available and have been shown to be relatively safe in the treatment of other diseases." @default.
• W2083963669 created "2016-06-24" @default.
• W2083963669 creator A5000233610 @default.
• W2083963669 creator A5014474065 @default.
• W2083963669 creator A5046088910 @default.
• W2083963669 date "2001-01-01" @default.
• W2083963669 modified "2023-10-16" @default.
• W2083963669 title "Cyclooxygenases and lipoxygenases as potential targets for treatment of pancreatic cancer" @default.
• W2083963669 cites W1211733072 @default.
• W2083963669 cites W1969846721 @default.
• W2083963669 cites W1974790340 @default.
• W2083963669 cites W1986170048 @default.
• W2083963669 cites W1986473192 @default.
• W2083963669 cites W1988008126 @default.
• W2083963669 cites W1995495200 @default.
• W2083963669 cites W1995978700 @default.
• W2083963669 cites W1998394615 @default.
• W2083963669 cites W2008574207 @default.
• W2083963669 cites W2030213691 @default.
• W2083963669 cites W2034346812 @default.
• W2083963669 cites W2038891714 @default.
• W2083963669 cites W2046331114 @default.
• W2083963669 cites W2050669947 @default.
• W2083963669 cites W2055298660 @default.
• W2083963669 cites W2062592710 @default.
• W2083963669 cites W2063110913 @default.
• W2083963669 cites W2069314125 @default.
• W2083963669 cites W2074203890 @default.
• W2083963669 cites W2075682082 @default.
• W2083963669 cites W2077984737 @default.
• W2083963669 cites W2078422697 @default.
• W2083963669 cites W2081324739 @default.
• W2083963669 cites W2085406903 @default.
• W2083963669 cites W2094298112 @default.
• W2083963669 cites W2095050968 @default.
• W2083963669 cites W2096451331 @default.
• W2083963669 cites W2109196042 @default.
• W2083963669 cites W2122020349 @default.
• W2083963669 cites W2126199519 @default.
• W2083963669 cites W2126853519 @default.
• W2083963669 cites W2131427975 @default.
• W2083963669 cites W2135247813 @default.
• W2083963669 cites W2138972132 @default.
• W2083963669 cites W2146550904 @default.
• W2083963669 cites W2152557257 @default.
• W2083963669 cites W2152659078 @default.
• W2083963669 cites W2160234181 @default.
• W2083963669 cites W2185486673 @default.
• W2083963669 cites W2376146086 @default.
• W2083963669 cites W2377593337 @default.
• W2083963669 cites W2412497467 @default.
• W2083963669 cites W256496835 @default.
• W2083963669 cites W4241607739 @default.
• W2083963669 cites W4252830963 @default.
• W2083963669 doi "https://doi.org/10.1159/000055827" @default.
• W2083963669 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12120207" @default.
• W2083963669 hasPublicationYear "2001" @default.
• W2083963669 type Work @default.
• W2083963669 sameAs 2083963669 @default.
• W2083963669 citedByCount "80" @default.
• W2083963669 countsByYear W20839636692012 @default.
• W2083963669 countsByYear W20839636692013 @default.
• W2083963669 countsByYear W20839636692014 @default.
• W2083963669 countsByYear W20839636692015 @default.
• W2083963669 countsByYear W20839636692016 @default.
• W2083963669 countsByYear W20839636692017 @default.
• W2083963669 countsByYear W20839636692018 @default.
• W2083963669 countsByYear W20839636692019 @default.
• W2083963669 countsByYear W20839636692020 @default.
• W2083963669 countsByYear W20839636692021 @default.
• W2083963669 countsByYear W20839636692022 @default.
• W2083963669 countsByYear W20839636692023 @default.
• W2083963669 crossrefType "journal-article" @default.
• W2083963669 hasAuthorship W2083963669A5000233610 @default.
• W2083963669 hasAuthorship W2083963669A5014474065 @default.
• W2083963669 hasAuthorship W2083963669A5046088910 @default.
• W2083963669 hasConcept C121608353 @default.
• W2083963669 hasConcept C126322002 @default.
• W2083963669 hasConcept C150903083 @default.
• W2083963669 hasConcept C190283241 @default.
• W2083963669 hasConcept C207001950 @default.
• W2083963669 hasConcept C2778764654 @default.
• W2083963669 hasConcept C2780210213 @default.
• W2083963669 hasConcept C502942594 @default.
• W2083963669 hasConcept C55493867 @default.
• W2083963669 hasConcept C555283112 @default.
• W2083963669 hasConcept C62112901 @default.
• W2083963669 hasConcept C71924100 @default.
• W2083963669 hasConcept C86803240 @default.
• W2083963669 hasConcept C96232424 @default.
• W2083963669 hasConceptScore W2083963669C121608353 @default.
• W2083963669 hasConceptScore W2083963669C126322002 @default.
• W2083963669 hasConceptScore W2083963669C150903083 @default.
• W2083963669 hasConceptScore W2083963669C190283241 @default.
• W2083963669 hasConceptScore W2083963669C207001950 @default.
• W2083963669 hasConceptScore W2083963669C2778764654 @default.
• W2083963669 hasConceptScore W2083963669C2780210213 @default.
• W2083963669 hasConceptScore W2083963669C502942594 @default.

• next